<DOC>
	<DOCNO>NCT01257451</DOCNO>
	<brief_summary>This study evaluate efficacy safety vildagliptin 50 mg bid elderly patient Type 2 Diabetes Mellitus ( T2DM ) .</brief_summary>
	<brief_title>Safety Efficacy Galvus Elderly Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>age : ≥ 70 year inclusive Visit 1. patient confirm diagnosis T2DM HbA1c ≥ 7 % ≤10.0 % central laboratory Visit 1 assess investigator inadequately control body mass index ( BMI ) range 1945kg/m2 FPG ≥ 270 mg/dL ( ≥ 15.0 mmol/L ) previous current participation vildagliptin clinical study . history hypersensitivity DPP4 inhibitor . concurrent medical condition may interfere interpretation efficacy safety data study . donation blood significant blood loss equal least one unit blood within past 2 week start study blood transfusion within past 12 week plan regular transfusion study period Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Type 2 Diabetes Mellitus , Vildagliptin , Elderly Patients</keyword>
</DOC>